Scynexis Inc (SCYX) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $4.50 (+1.12%), Market cap $0.05B, 52-week low–high $0.58 ~ $1.18.
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Financial statements, price targets, institutional (13F) holdings and related news for Scynexis Inc are updated in real time on BlackAll Trade.
Scynexis Inc trades at $4.50 (+1.12%). Real-time quotes and charts are available on BlackAll Trade.
Scynexis Inc has a market cap of about $0.05B.
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offer